7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Magnolol inhibits venous remodeling in mice

      research-article
      , , , ,
      Scientific Reports
      Nature Publishing Group UK

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Due to gravity the venous vasculature in the lower extremities is exposed to elevated pressure levels which may be amplified by obesity or pregnancy. As a consequence, venules dilate and may be slowly transformed into varicose or spider veins. In fact, chronically elevated venous pressure was sufficient to cause the corkscrew-like enlargement of superficial veins in mice. We hypothesized that biomechanical activation of endothelial cells contributes to this process and investigated the inhibitory capacity of Magnolol in this context – a natural compound that features multiple properties counteracting cellular stress. While Magnolol did not influence endothelial capillary sprout formation, it interfered with proliferation, ERK1/2 activity, gelatinase activity as well as baseline production of reactive oxygen species in these cells or murine veins. The anti-oxidative and anti-proliferative capacity of Magnolol was mediated through stimulation of heme oxygenase-1 expression. Finally, local transdermal application of Magnolol attenuated pressure-mediated development of varicose/spider veins in mice and was accompanied by the absence of proliferating and MMP-2 positive endothelial cells. Collectively, our data identified Magnolol as a potent inhibitor of biomechanically evoked endothelial cell activity during pressure-mediated venous remodeling processes which contribute to the development of varicose and spider veins.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum.

          The Society for Vascular Surgery (SVS) and the American Venous Forum (AVF) have developed clinical practice guidelines for the care of patients with varicose veins of the lower limbs and pelvis. The document also includes recommendations on the management of superficial and perforating vein incompetence in patients with associated, more advanced chronic venous diseases (CVDs), including edema, skin changes, or venous ulcers. Recommendations of the Venous Guideline Committee are based on the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system as strong (GRADE 1) if the benefits clearly outweigh the risks, burden, and costs. The suggestions are weak (GRADE 2) if the benefits are closely balanced with risks and burden. The level of available evidence to support the evaluation or treatment can be of high (A), medium (B), or low or very low (C) quality. The key recommendations of these guidelines are: We recommend that in patients with varicose veins or more severe CVD, a complete history and detailed physical examination are complemented by duplex ultrasound scanning of the deep and superficial veins (GRADE 1A). We recommend that the CEAP classification is used for patients with CVD (GRADE 1A) and that the revised Venous Clinical Severity Score is used to assess treatment outcome (GRADE 1B). We suggest compression therapy for patients with symptomatic varicose veins (GRADE 2C) but recommend against compression therapy as the primary treatment if the patient is a candidate for saphenous vein ablation (GRADE 1B). We recommend compression therapy as the primary treatment to aid healing of venous ulceration (GRADE 1B). To decrease the recurrence of venous ulcers, we recommend ablation of the incompetent superficial veins in addition to compression therapy (GRADE 1A). For treatment of the incompetent great saphenous vein (GSV), we recommend endovenous thermal ablation (radiofrequency or laser) rather than high ligation and inversion stripping of the saphenous vein to the level of the knee (GRADE 1B). We recommend phlebectomy or sclerotherapy to treat varicose tributaries (GRADE 1B) and suggest foam sclerotherapy as an option for the treatment of the incompetent saphenous vein (GRADE 2C). We recommend against selective treatment of perforating vein incompetence in patients with simple varicose veins (CEAP class C(2); GRADE 1B), but we suggest treatment of pathologic perforating veins (outward flow duration ≥500 ms, vein diameter ≥3.5 mm) located underneath healed or active ulcers (CEAP class C(5)-C(6); GRADE 2B). We suggest treatment of pelvic congestion syndrome and pelvic varices with coil embolization, plugs, or transcatheter sclerotherapy, used alone or together (GRADE 2B). Copyright © 2011 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Natural products derived from plants as a source of drugs

            Nature, the master of craftsman of molecules created almost an inexhaustible array of molecular entities. It stands as an infinite resource for drug development, novel chemotypes and pharmacophores, and scaffolds for amplification into efficacious drugs for a multitude of disease indications and other valuable bioactive agents. Since time immemorial, natural products have been the backbone of traditional system of healing throughout the globe, and have also been an integral part of history and culture. Although the use of bioactive natural products as herbal drug preparations dates back hundreds, even thousands, of years ago, their application as isolated and characterized compounds to modern drug discovery and development started only in the 19th century. It has been well documented that natural products played critical roles in modern drug development, especially for antibacterial and antitumor agents. Even though popularity of the synthetic products increased due to its production cost, time effectiveness, easy quality control, stringent regulation and quick effects, but their safety and efficacy was always remained questionable, resulting in the dependence on the natural products by more than 80% of the total population in the developing world, because of its time tested safety and efficacy. A huge number of natural product-derived compounds in various stages of clinical development highlighted the existing viability and significance of the use of natural products as sources of new drug candidates. Until recently, plants were an important source of novel pharmacologically active compounds with many blockbuster drugs being derived directly or indirectly from plants. Despite the current preoccupation with synthetic chemistry as a vehicle to discover and manufacture drugs, the contribution of plants to disease treatment and prevention is still enormous. Even at the dawn of 21st century, 11% of the 252 drugs considered as basic and essential by the WHO were exclusively of flowering plant origin. Obviously natural products will continue to be extremely important as sources of medicinal agents. In addition to the natural products which have found direct medicinal application as drug entities, many others can serve as chemical models or templates for the design, synthesis, and semi synthesis of novel substances for treating humankind's diseases. Although there are some new approaches to drug discovery, such as combinatorial chemistry and computer-based molecular modeling design, and many drugs are made by synthetic chemistry, none of them can replaced the important role of natural products in drug discovery and development as most of the core structures or scaffolds for synthetic chemicals are based upon natural products. According to Newman and Cragg 2012, the utility of natural products as sources of novel structures is still alive and well. Up to 50% the approved drugs during the last 30 years are from either directly or indirectly from natural products and in the area of cancer, over the time frame from around the 1940s to date, of the 175 small molecules 85 actually being either natural products or directly derived there from. The use of plants as medicines has a long history in the treatment of various diseases. The plant-derived compounds have a long history of clinical use, better patient tolerance and acceptance. To date, 35,000-70,000 plant species have been screened for their medicinal use. Plants especially those with ethnopharmacological uses have been the primary sources of medicine for early drug discovery. Fabricant and Farnsworth, (2001) reported that, 80% of 122 plant derived drugs were related to their original ethnopharmacological purposes. Current drug discovery from plants mainly relied on bioactivity–guided fractionation and led to isolation of many important anticancer drugs such as paclitaxel, camptothecin etc. The first commercial pure natural product introduced for therapeutic use is morphine marketed by Merck in 1826, and the first semi-synthetic pure drug aspirin, based on a natural product salicin isolated from Salix alba, was introduced by Bayer in 1899. This led to the isolation of early drugs such as cocaine, codeine, digitoxin, quinine and pilocarpine, of which some are still in use and several other recent plant derived compounds, which have undergone development and have been marketed as drugs which include Paclitaxel from Taxus brevifolia for lung, ovarian and breast cancer, Artemisinin from traditional Chinese plant Artemisia annua to combat multidrug resistant malaria, Silymarin extracted from the seeds of Silybum marianum for the treatment of liver diseases. There is growing evidence that the old molecules are finding new applications through better understanding of molecular biology and clinical observations. For instance, the alkaloid, forskolin from Coleus forskohlii and phytochemicals from Stephania glabra, are now being rediscovered as adenylate cyclase and nitric oxide activators, which may help in preventing conditions including obesity and atherosclerosis. During the last decade few plant derived drugs have been launched include Arteether, endoperoxide sesquiterpene lactone and semisynthetic natural product derived from Artemisinin used in malarial treatment, Nitisinone derived from natural product Leptospermone (Callistemon citrinus) is used in treatment of antityrosinaemia, galantamine is a natural alkaloid (obtained from Galanthus nivalis) for Alzhemer's, apomorphine is a semisynthetic compound derived from morphine (Papaver somniferum) used in Parkinson's disease, Tiotropium a derivative of atropine from Atropa belladonna in chronic obstructive pulmonary disease, Dronabinol and Cannabidiol obtained from cannabis plant (Cannabis sativa) and Capsaicin active compound from Capsicum annuum are used as pain relievers. Natural products discovered so far have played a vital role in improving the human health and have been the drugs of choice despite facing a tough competition from compounds derived from computational and combinatorial chemistry, due to their safety and efficacy. The most striking feature of natural products in connection to their long lasting importance in drug discovery is their structural diversity that is still largely untapped. Revitalization of the natural products is bringing newer challenges with respect to quality control and standardization along with cost effectiveness. The renewed interest in the development of natural products requires the confluence of the modern techniques and harmonization of regulations related to their research and development between various fields of science.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Role of endothelial cell metabolism in vessel sprouting.

              Endothelial cells (ECs) are quiescent for years but can plastically switch to angiogenesis. Vascular sprouting relies on the coordinated activity of migrating tip cells at the forefront and proliferating stalk cells that elongate the sprout. Past studies have identified genetic signals that control vascular branching. Prominent are VEGF, activating tip cells, and Notch, which stimulates stalk cells. After the branch is formed and perfused, ECs become quiescent phalanx cells. Now, emerging evidence has accumulated indicating that ECs not only adapt their metabolism when switching from quiescence to sprouting but also that metabolism regulates vascular sprouting in parallel to the control by genetic signals. Copyright © 2013 Elsevier Inc. All rights reserved.
                Bookmark

                Author and article information

                Contributors
                korff@physiologie.uni-heidelberg.de
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                19 December 2017
                19 December 2017
                2017
                : 7
                : 17820
                Affiliations
                ISNI 0000 0001 2190 4373, GRID grid.7700.0, Institute of Physiology and Pathophysiology, , Division of Cardiovascular Physiology, Heidelberg University, ; Heidelberg, Germany
                Article
                17910
                10.1038/s41598-017-17910-0
                5736655
                4086d323-e4d3-43e8-89f4-0a7d5e5f5137
                © The Author(s) 2017

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 12 June 2017
                : 4 December 2017
                Categories
                Article
                Custom metadata
                © The Author(s) 2017

                Uncategorized
                Uncategorized

                Comments

                Comment on this article